Abstract
Purpose: This trial was conducted to assess the toxicity and efficacy of 131I-Lym-1 in patients with either malignant B-cell non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL) using low-dose, fractionated radioimmunotherapy (RIT). Materials and Methods: Thirty adult patients who had advanced B-cell malignancies (25 NHL and 5 CLL) had progressed despite standard therapy; 12 patients entered the trial with Karnofsky performance status (KPS) of equal to or greater than 60. Patients were treated with a series of intravenous doses of 131I-Lym-1 with a goal of reaching a cumulative dose in each patient of at least 300 mCi. All patients were Lym-1 reactive. Clinical responses and immediate toxicity were evaluable in all 30 patients and delayed toxicity in 26. Results: Toxicity to Lym-1 antibody occurred with 28% of the 176 doses and was transient. Human antimouse antibodies (HAMA) were generated in 30% after a mean of 4 doses, but interrupted therapy in only 10% of the patients. Thrombocytopenia was dose- limiting: there were no deaths due to toxicity. Tumor regression occurred in 25 (83%) of the patients and was great enough, and durable enough, in 17 (57%) to qualify them as responders; 13 NHL patients and 4 CLL patients. Advanced disease often interrupted therapy prematurely. However, 18 patients received at least 180 mCi of 131I-Lym-1; 17 (94%) of these responded to the therapy. Conclusion: Although advanced disease often interrupted therapy prematurely, the results from 131I-Lym-1 therapy are clearly promising and warrant additional trials.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 239-254 |
| Number of pages | 16 |
| Journal | Cancer Biotherapy and Radiopharmaceuticals |
| Volume | 13 |
| Issue number | 4 |
| State | Published - 1998 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Pharmacology
- Oncology
Cite this
Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-LYM-1 antibody. / Denardo, Gerald L; DeNardo, Sally J.; Lamborn, Kathleen R.; Goldstein, Desiree S.; Levy, Norman B.; Lewis, Jerry P.; O'Grady, Lois F.; Raventos, Antolin; Kroger, Linda A.; Macey, Daniel J.; McGahan, John P; Mills, Stanley L.; Shen, Sui.
In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 13, No. 4, 1998, p. 239-254.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-LYM-1 antibody
AU - Denardo, Gerald L
AU - DeNardo, Sally J.
AU - Lamborn, Kathleen R.
AU - Goldstein, Desiree S.
AU - Levy, Norman B.
AU - Lewis, Jerry P.
AU - O'Grady, Lois F.
AU - Raventos, Antolin
AU - Kroger, Linda A.
AU - Macey, Daniel J.
AU - McGahan, John P
AU - Mills, Stanley L.
AU - Shen, Sui
PY - 1998
Y1 - 1998
N2 - Purpose: This trial was conducted to assess the toxicity and efficacy of 131I-Lym-1 in patients with either malignant B-cell non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL) using low-dose, fractionated radioimmunotherapy (RIT). Materials and Methods: Thirty adult patients who had advanced B-cell malignancies (25 NHL and 5 CLL) had progressed despite standard therapy; 12 patients entered the trial with Karnofsky performance status (KPS) of equal to or greater than 60. Patients were treated with a series of intravenous doses of 131I-Lym-1 with a goal of reaching a cumulative dose in each patient of at least 300 mCi. All patients were Lym-1 reactive. Clinical responses and immediate toxicity were evaluable in all 30 patients and delayed toxicity in 26. Results: Toxicity to Lym-1 antibody occurred with 28% of the 176 doses and was transient. Human antimouse antibodies (HAMA) were generated in 30% after a mean of 4 doses, but interrupted therapy in only 10% of the patients. Thrombocytopenia was dose- limiting: there were no deaths due to toxicity. Tumor regression occurred in 25 (83%) of the patients and was great enough, and durable enough, in 17 (57%) to qualify them as responders; 13 NHL patients and 4 CLL patients. Advanced disease often interrupted therapy prematurely. However, 18 patients received at least 180 mCi of 131I-Lym-1; 17 (94%) of these responded to the therapy. Conclusion: Although advanced disease often interrupted therapy prematurely, the results from 131I-Lym-1 therapy are clearly promising and warrant additional trials.
AB - Purpose: This trial was conducted to assess the toxicity and efficacy of 131I-Lym-1 in patients with either malignant B-cell non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL) using low-dose, fractionated radioimmunotherapy (RIT). Materials and Methods: Thirty adult patients who had advanced B-cell malignancies (25 NHL and 5 CLL) had progressed despite standard therapy; 12 patients entered the trial with Karnofsky performance status (KPS) of equal to or greater than 60. Patients were treated with a series of intravenous doses of 131I-Lym-1 with a goal of reaching a cumulative dose in each patient of at least 300 mCi. All patients were Lym-1 reactive. Clinical responses and immediate toxicity were evaluable in all 30 patients and delayed toxicity in 26. Results: Toxicity to Lym-1 antibody occurred with 28% of the 176 doses and was transient. Human antimouse antibodies (HAMA) were generated in 30% after a mean of 4 doses, but interrupted therapy in only 10% of the patients. Thrombocytopenia was dose- limiting: there were no deaths due to toxicity. Tumor regression occurred in 25 (83%) of the patients and was great enough, and durable enough, in 17 (57%) to qualify them as responders; 13 NHL patients and 4 CLL patients. Advanced disease often interrupted therapy prematurely. However, 18 patients received at least 180 mCi of 131I-Lym-1; 17 (94%) of these responded to the therapy. Conclusion: Although advanced disease often interrupted therapy prematurely, the results from 131I-Lym-1 therapy are clearly promising and warrant additional trials.
UR - http://www.scopus.com/inward/record.url?scp=7844233336&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=7844233336&partnerID=8YFLogxK
M3 - Article
C2 - 10850360
AN - SCOPUS:7844233336
VL - 13
SP - 239
EP - 254
JO - Cancer Biotherapy and Radiopharmaceuticals
JF - Cancer Biotherapy and Radiopharmaceuticals
SN - 1084-9785
IS - 4
ER -